Chronic high dose transdermal nicotine in Parkinson's disease: An open trial

European Journal of Neurology

Volumn 14, Issue 12, 2007, Pages 1313-1316

  Villafane, G ^b   Cesaro, P ^a,b   Rialland, A ^a   Baloul, S ^a   Azimi, S ^c   Bourdet, C ^b   Le Houezec, J ^d   Macquin Mavier, I ^a   Maison, P ^a  

^a HENRI MONDOR HOSPITAL   (France)

^b INSERM   (France)

^c SAINT LOUIS HOSPITAL   (France)

^d Amzer Glas   (France)

Author keywords

Clinical trial; Nicotine; Parkinson's disease; Transdermal

Indexed keywords

LEVODOPA; NICOTINE; NICOTINE GUM;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG SAFETY; FEASIBILITY STUDY; HUMAN; IDIOPATHIC DISEASE; INSOMNIA; IRRITABILITY; MALE; MOTOR PERFORMANCE; NAUSEA; ORTHOSTATIC HYPOTENSION; PARKINSON DISEASE; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; TREATMENT OUTCOME; UNIFIED PARKINSON DISEASE RATING SCALE; URINARY EXCRETION; VOMITING;

ADMINISTRATION, CUTANEOUS; DOPAMINE AGONISTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG SYNERGISM; HUMANS; MALE; MIDDLE AGED; NAUSEA; NICOTINE; NICOTINIC AGONISTS; PARKINSON DISEASE; PILOT PROJECTS; TREATMENT OUTCOME;

EID: 36248953114     PISSN: 13515101     EISSN: 14681331     Source Type: Journal    
DOI: 10.1111/j.1468-1331.2007.01949.x     Document Type: Article

References (13)

1. Olanow CW, Tatton WG. Etiology and pathogenesis of Parkinson's disease. Annual Review of Neuroscience 1999 22: 123 144.
2. Quik M. Smoking, nicotine and Parkinson's disease. Trends in Neurosciences 2004 27: 561 568.
3. Fagerström KO, Pomerleau O, Giordani B, Stelson F. Nicotine may relieve symptoms of Parkinson's disease. Psychopharmacology (Berlin) 1994 116: 117 119.
4. Villafane G, Degos JD, Lagrue G, Petras S, Cesaro P. Long term nicotine treatment in Parkinson's disease: report of a case. Movement Disorders 2000 15: 654.
5. Ebersbach G, Stock M, Müller J, Wenning G, Wissel J, Poewe W. Worsening of motor performance in patients with Parkinson's disease following transdermal nicotine administration. Movment Disorders 1999 14: 1011 1013.
6. Vieregge A, Sieberer M, Sieberer M, et al. Transdermal nicotine in PD: a randomized, double-blind, placebo-controlled study. Neurology 2001 57: 1032 1035.
7. Kelton MC, Kahn HJ, Conrath CL, Newhouse PA. The effect of nicotine in Parkinson's disease. Brain Cognition 2000 43: 274 282.
8. Lemay S, Chouinard S, Blanchet P, et al. Lack of efficacy of a nicotine transdermal treatment on motor and cognitive deficits in Parkinson's disease. Progress in Neuro-Psychopharmacology and Biological Psychiatry 2004 28: 31 39.
9. Villafane G, Mimran A, Degos JD, Lagrue G, Cesaro P. Long-term nicotine administration can improve Parkinson's disease: report of a case after three years of treatment. Revista Neurologica Argentina 2002 27: 95 97.
10. Daniel SE, Lees AJ. Parkinson's disease Society Brain Bank, London: overview and research. Journal of Neural Transmission. Supplementum 1993 39: 165 172.
11. Wonnacott S, Kaiser S, Mogg A, Soliakov L, Jones IW. Presynaptic nicotinic receptors modulating dopamine release in the rat striatum. European Journal of Pharmacology 2000 393: 51 58.
12. Newhouse P, Singh A, Potter A. Nicotine and nicotinic receptor involvement in neuropsychiatric disorders. Current Topics in Medicinal Chemistry 2004 4: 267 282.
13. Le Foll B, Diaz J, Sokoloff P. Increased dopamine D3 receptor expression accompanying behavioral sensitization to nicotine in rats. Synapse 2003 47: 176 183.